Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant

NEXT STORY
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
PREV STORY
Kinross announces acquisition of Great Bear Resources
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News

Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

author_avatar
NASDAQ Market News

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk ...

author_avatar
NASDAQ Market News